http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#Head http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#assertion http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#provenance http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#pubinfo http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#assertion http://purl.obolibrary.org/obo/DOID_10763 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_10763 http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00700 http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#association http://www.w3.org/2000/01/rdf-schema#label for all patients eplerenone tablets are contraindicated in all patients with serum potassium 5 5 meq l at initiation creatinine clearance 3 ml min or concomitant administration of strong cyp3a4 inhibitors e g ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir and nelfinavir see drug interactions 7 1 cyp3a4 inhibitors clinical pharmacology 12 3 pharmacokinetics for patients treated for hypertension eplerenone tablets is contraindicated for the treatment of hypertension in patients with type 2 diabetes with microalbuminuria serum creatinine 2 mg dl in males or 1 8 mg dl in females creatinine clearance 5 ml min or concomitant administration of potassium supplements or potassium sparing diuretics e g amiloride spironolactone or triamterene see warnings and precautions 5 1 hyperkalemia adverse reactions 6 2 clinical laboratory test findings 7 drug interactions clinical pharmacology 12 3 pharmacokinetics for all patients serum potassium 5 5 meq l at initiation 4 creatinine clearance 3 ml min 4 concomitant use with strong cyp3a4 inhibitors 4 7 1 for the treatment of hypertension type 2 diabetes with microalbuminuria 4 serum creatinine 2 mg dl in males 1 8 mg dl in females 4 creatinine clearance 5 ml min 4 concomitant use of potassium supplements or potassium sparing diuretics 4 http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00700 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#provenance http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#pubinfo http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#sig http://purl.org/nanopub/x/hasSignature VPX3+yTpfORo6AeUODBGVsyvRsB+decUKsUS82MtIhthlmwdRaA0Q/KNe/78xinftMMV2P04HrX8SWlVpxoxVPGjWRiP/uAkuDIRG9zq7vBGi11Lm1ufVRvX+ZF25AUiJlfamWTG0WonXRXouZA7atV+o5Fty/2zQd53d4DX7jI= http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o http://purl.org/dc/terms/created 2021-06-12T15:36:15.751+02:00 http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs